WO2007040565A3 - Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists - Google Patents

Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists Download PDF

Info

Publication number
WO2007040565A3
WO2007040565A3 PCT/US2005/042551 US2005042551W WO2007040565A3 WO 2007040565 A3 WO2007040565 A3 WO 2007040565A3 US 2005042551 W US2005042551 W US 2005042551W WO 2007040565 A3 WO2007040565 A3 WO 2007040565A3
Authority
WO
WIPO (PCT)
Prior art keywords
hif
receptor antagonists
cancer
adenosine
disoders
Prior art date
Application number
PCT/US2005/042551
Other languages
French (fr)
Other versions
WO2007040565A9 (en
WO2007040565A2 (en
Inventor
Pier Andrea Borea
Pier Giovani Baraldi
Stefania Merighi
Stephen Maclennan
Edward Leung
Allan Moorman
Original Assignee
King Pharmaceuticals Res & Dev
Pier Andrea Borea
Pier Giovani Baraldi
Stefania Merighi
Stephen Maclennan
Edward Leung
Allan Moorman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Res & Dev, Pier Andrea Borea, Pier Giovani Baraldi, Stefania Merighi, Stephen Maclennan, Edward Leung, Allan Moorman filed Critical King Pharmaceuticals Res & Dev
Priority to CA002586420A priority Critical patent/CA2586420A1/en
Priority to AU2005336924A priority patent/AU2005336924A1/en
Priority to JP2007543474A priority patent/JP2008520746A/en
Priority to EP05858564A priority patent/EP1827445A2/en
Publication of WO2007040565A2 publication Critical patent/WO2007040565A2/en
Priority to IL183307A priority patent/IL183307A0/en
Publication of WO2007040565A9 publication Critical patent/WO2007040565A9/en
Publication of WO2007040565A3 publication Critical patent/WO2007040565A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to the use of adenosine receptor antagonists, preferably A3 receptor antagonists, either alone or in combination with other agents for the treatment, prevention and/or management of diseases or disorders associated with overexpression of HIF-lα and/or increased HIF-1 α activity (e.g., cancer, respiratory disease). The methods and compositions of the invention are particularly useful for preventing, treating, or ameliorating symptoms associated with a cancer, disease or disorder associated with hypoxia-inducible factor 1-α (HIF-lα) using the A3 receptor antagonists of the invention. The present invention provides methods to inhibit the growth of tumors, particularly solid tumors and more particularly hypoxic tumors.
PCT/US2005/042551 2004-11-22 2005-11-22 Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists WO2007040565A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002586420A CA2586420A1 (en) 2004-11-22 2005-11-22 Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
AU2005336924A AU2005336924A1 (en) 2004-11-22 2005-11-22 Enhancing treatment of cancer and HIF-1 mediated disoders with adenosine A3 receptor antagonists
JP2007543474A JP2008520746A (en) 2004-11-22 2005-11-22 Accelerated treatment of cancer and HIF-1 mediated diseases using an adenosine A3 receptor antagonist
EP05858564A EP1827445A2 (en) 2004-11-22 2005-11-22 Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
IL183307A IL183307A0 (en) 2004-11-22 2007-05-17 Enhancing treatment of cancer and hif-1 mediated disorders with adenosine a3 receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63055704P 2004-11-22 2004-11-22
US60/630,557 2004-11-22

Publications (3)

Publication Number Publication Date
WO2007040565A2 WO2007040565A2 (en) 2007-04-12
WO2007040565A9 WO2007040565A9 (en) 2007-07-05
WO2007040565A3 true WO2007040565A3 (en) 2009-04-16

Family

ID=37906593

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/042551 WO2007040565A2 (en) 2004-11-22 2005-11-22 Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists

Country Status (6)

Country Link
EP (1) EP1827445A2 (en)
JP (1) JP2008520746A (en)
AU (1) AU2005336924A1 (en)
CA (1) CA2586420A1 (en)
IL (1) IL183307A0 (en)
WO (1) WO2007040565A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102036962B (en) * 2008-01-29 2013-08-07 卫材R&D管理有限公司 Combined use of angiogenesis inhibitor and taxane

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ525324A (en) 2000-10-20 2005-03-24 Eisai Co Ltd Nitrogenous aromatic ring compounds
US7994159B2 (en) 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
CN100450998C (en) 2003-11-11 2009-01-14 卫材R&D管理有限公司 Urea derivative and process for producing the same
WO2006030826A1 (en) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. Medicinal composition
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
WO2007136103A1 (en) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
JP5638244B2 (en) 2007-11-09 2014-12-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 Combination of angiogenesis inhibitors and antitumor platinum complexes
EA022271B1 (en) * 2008-11-14 2015-12-30 Байер Интеллектуэль Проперти Гмбх Heterocyclically substituted aryl compounds as hif inhibitors
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
WO2012144463A1 (en) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Therapeutic agent for tumor
JP6038128B2 (en) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 A biomarker for predicting and evaluating the reactivity of thyroid and renal cancer subjects to lenvatinib compounds
KR20150098605A (en) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 Amorphous form of quinoline derivative, and method for producing same
US9782428B2 (en) 2013-03-18 2017-10-10 Northeastern University Method for generation of broadly neutralizing anti-pathogen antibodies
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
TWI721954B (en) 2014-08-28 2021-03-21 日商衛材R&D企管股份有限公司 High-purity quinoline derivative and production method thereof
SI3263106T1 (en) 2015-02-25 2024-02-29 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
US20230113037A1 (en) * 2019-08-12 2023-04-13 Bayer Aktiengesellschaft [1,2,4]triazolo[1,5-c]quinazolin-5-amines
WO2022029063A1 (en) 2020-08-04 2022-02-10 Bayer Aktiengesellschaft Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines
CN114574580B (en) * 2022-02-14 2022-11-29 山东大学 Application of targeted A2BR combined chemotherapy in treatment of triple negative breast cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019360A2 (en) * 1999-09-10 2001-03-22 Can-Fite Biopharma Ltd. Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6326390B1 (en) * 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
US6407236B1 (en) * 1998-09-16 2002-06-18 Medco Research, Inc. Adenosine A3 receptor modulators
US20030144266A1 (en) * 1998-09-16 2003-07-31 Baraldi Pier Giovanni Adenosine A3 receptor modulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326390B1 (en) * 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
US6407236B1 (en) * 1998-09-16 2002-06-18 Medco Research, Inc. Adenosine A3 receptor modulators
US20030144266A1 (en) * 1998-09-16 2003-07-31 Baraldi Pier Giovanni Adenosine A3 receptor modulators
WO2001019360A2 (en) * 1999-09-10 2001-03-22 Can-Fite Biopharma Ltd. Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VAUPEL, P. ET AL.: "The Role of Hypoxia-Induced Factors in Tumor Progression", THE ONCOLOGIST, vol. 9, no. SUP.5, September 2004 (2004-09-01), pages 10 - 17 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102036962B (en) * 2008-01-29 2013-08-07 卫材R&D管理有限公司 Combined use of angiogenesis inhibitor and taxane

Also Published As

Publication number Publication date
JP2008520746A (en) 2008-06-19
AU2005336924A1 (en) 2007-04-12
IL183307A0 (en) 2008-04-13
WO2007040565A9 (en) 2007-07-05
WO2007040565A2 (en) 2007-04-12
CA2586420A1 (en) 2007-04-12
EP1827445A2 (en) 2007-09-05

Similar Documents

Publication Publication Date Title
WO2007040565A3 (en) Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
TNSN08277A1 (en) Materials and methods for treating chronic fibrotic disease
WO2006055970A3 (en) Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists
MX2007004551A (en) Thiadiazole compounds and methods of use.
WO2005051308A3 (en) Methods of treating diseases and disorders by targeting multiple kinases
EP2331095A4 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2005092009A3 (en) Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
MY176679A (en) Use of nutritional compositions for preventing disorders
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
IL219857A0 (en) Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis
WO2005097125A3 (en) Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease
SG155188A1 (en) Pyrrole derivatives as pharmaceutical agents
WO2004084835A3 (en) Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
WO2004096148A3 (en) Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof
MX2009011366A (en) Methods and compositions for treating and monitoring treatment of il-13-associated disorders.
TW200633980A (en) Pyridones useful as inhibitors of kinases
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
HK1118579A1 (en) Adamts13-comprising compositions having thrombolytic activity
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2007058990A3 (en) Therapy using cytokine inhibitors
WO2006088925A3 (en) Use of il17-f in diagnosis and therapy of airway inflammation
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2586420

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 183307

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2007543474

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005336924

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005858564

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005336924

Country of ref document: AU

Date of ref document: 20051122

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005336924

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005858564

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005858564

Country of ref document: EP